Eton Pharmaceuticals
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a privately held company, is focused on the development and commercialization of innovative sterile injectable product candidates utilizing the FDA 505(b)(2) regulatory pathway.60 articles with Eton Pharmaceuticals
-
The U.S. FDA is starting off August with a mix of PDUFA dates for acne products, seizure medications and a new manufacturing process for a non-opioid pain killer. Here’s a look.
-
Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection)
6/15/2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
-
Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector
6/15/2021
Eton today announced that it has acquired U.S. and Canadian rights to Crossject’s ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.
-
The month of June continues to be busy for the U.S. Food and Drug Administration. There are three PDUFA dates on the calendar for this week. Here’s a look.
-
Eton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection
5/28/2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) in response to the submission of its New Drug Application (NDA) for dehydrated alcohol injection for the treatment of methanol poisoning.
-
It’s a busy week for the U.S. Food and Drug Administration, with a number of drug approvals on the calendar and an advisory committee meeting. Read on for more information.
-
Eton Pharmaceuticals Reports Record Revenue and Earnings
5/13/2021
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the first quarter ended March 31, 2021 and provided an update on business progress.
-
Eton Pharmaceuticals to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
5/4/2021
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it will report first quarter 2021 financial and operating results on Thursday, May 13, 2021.
-
Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors
3/17/2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021.
-
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results
3/16/2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on business progress.
-
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16, 2021
3/4/2021
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, announced that it will report fourth quarter and full year 2020 financial and operating results on Tuesday, March 16, 2021.
-
Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference
2/16/2021
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10 th Annual SVB Leerink Global Healthcare Conference from February 24 th through February 26 th .
-
Azurity Pharmaceuticals Announces Three New Neurology Products
2/9/2021
Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today the purchase of the neurology portfolio from Eton Pharmaceuticals.
-
Eton Pharmaceuticals Announces Sale of Neurology Portfolio
2/8/2021
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity Pharmaceuticals.
-
Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE
1/14/2021
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc (LSE AIM: DNL)
-
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral SolutionApplication Assigned a PDUFA Date of August 6, 2021
12/17/2020
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for topiramate oral solution.
-
Eton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States
11/24/2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the full availability of ALKINDI® SPRINKLE for sale and distribution in the United States.
-
Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results
11/12/2020
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, reported financial results for the third quarter ended September 30, 2020 and provided an update on business progress.
-
Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020
11/4/2020
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, announced that it will report third quarter 2020 financial and operating results on Thursday, November 12, 2020.
-
Eton Pharmaceuticals Announces Closing of Public Offering
10/16/2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000 shares of common stock at a public offering price of $7.00 per share. The total offering included 420,000 shares sold as a result of the underwriter’s exercise of its overallotment option in full.